本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the latest developments and trends in healthcare technology in Taiwan. China Medical University (CMU) and Healthcare System unveiled groundbreaking advancements in AI-driven drug discovery and cancer therapy at the latest 8th Healthcare Expo. These achievements cement CMU and Healthcare System's position as a global leader in healthcare innovation, setting new benchmarks for the biomedical industry. CMU and Healthcare System (Taiwan) highlights groundbreaking AI-driven drug discovery and unveils the latest advancements in healthcare innovations and their clinical applications. Dr. Chang-Hai Tsai, Chairman of CMU and Healthcare System, emphasized the institution's commitment to cutting-edge research and international collaboration. By partnering with Kyoto University, CMU and Healthcare System has established a global research center to spearhead advancements in cancer research, regenerative medicine, and AI-powered drug discovery. A Milestone in Cancer Therapy: Allogeneic CAR-T Achieves 90% Tumor Reduction CMU and Healthcare System revealed the world's first allogeneic CAR-T therapy for solid cancers, developed by Ever Supreme Bio Technology. This therapy has demonstrated an unprecedented tumor reduction rate of over 90% in pre-clinical studies. Human clinical trials are underway, with FDA approval marking a pivotal moment in solid tumor treatment. Precision Medicine Breakthroughs: Exosome Technology and AI Integration Shine-On Biomedical and Shine Out Bio Technology are revolutionizing precision medicine through exosome technology. Their innovations include: SOA101 Trispecific Antibody: A nanobody-based platform combining two immune checkpoint inhibitors, now in FDA-reviewed Phase I/IIa trials for cancer therapy. SOB100 HLA-G Targeted Exosome: Delivering drugs with pinpoint precision to tumors, this platform enhances efficacy while minimizing side effects. Human clinical trials for these technologies are set to begin in 2025, promising to transform cancer and neurodegenerative disease treatments. AI-Powered Healthcare Solutions CMU and Healthcare System's AI-driven initiatives include: Child Growth Assessment System: AI generates detailed diagnostic reports for personalized treatment planning. HiThings Tele-ICU: This state-of-the-art system integrates real-time patient data with 3D modeling for enhanced critical care management. Smart Health Scheduling: AI optimizes health examination processes to streamline care delivery. Computer-assisted detection platform for Tc-99mTRODAT-1: AI analyzes brain images and visual scales to assist in diagnosing central nervous system motor disorders. Long Term Care Record System and Medical Information Revise Assistant (MIRA): Enhances medical record accuracy and efficiency, allowing healthcare professionals to focus on patient care. Specialized Healthcare Innovations CMUH continues to lead in cutting-edge treatments: MRgFUS for Parkinson's Disease: A non-invasive, MRI-guided therapy offering new hope for patients. Proton Therapy Center: Delivering precision cancer treatments with reduced side effects. Gout Risk Prediction: Genetic testing for tailored patient management. Global Collaboration with Kyoto University The newly established CMU-Kyoto University Global Research Center strengthens ties in cancer research, translational medicine, and regenerative therapies. As part of this initiative, CMU Research Park integrates academic and industrial expertise to drive groundbreaking developments from laboratory research to clinical applications. Advancing Healthcare Through Innovation Dr. Der-Yang Cho, Superintendent of CMUH, highlighted AI's transformative role in drug discovery and clinical applications. CMU and Healthcare System remains at the forefront of healthcare innovation, bridging AI, biotechnology, and clinical practice to redefine the future of medicine. CMU and Healthcare System's pioneering work at the Healthcare Expo Taiwan underscores Taiwan's growing influence in global healthcare. With a focus on collaboration and innovation, CMU and Healthcare System is not just shaping the future of medicine—it's leading it. ContactCarolyn Chen100709@tool.caaumed.org.tw
BEIJING, Dec. 27, 2024 /PRNewswire/ -- The 2nd Northeast Asia Finance Conference and 2024 "Revitalizing Liaoning with Finance" Excellent Cases Release kicked off on Tuesday in Shenyang, capital of northeast China's Liaoning Province, aiming to further deepen financial openness and cooperation in the Northeast Asian region and advance construction of a regional financial center. The main forum held a series of activities, including an opening ceremony, two round-table dialogues on "finance + biomedical industry" and "finance + cultural industry", a symposium for foreign financial institutions, a seminar on innovative development of financial clusters, a forum on development of technology and finance, a forum on industrial low-carbon transformation and financial innovation, as well as an enterprise project roadshow and industry-finance matchmaking event. During the conference themed on "accelerating the construction of a regional financial center in Northeast Asia and creating a new highland for opening up", excellent cases of revitalizing Liaoning through finance in 2024 were unveiled and the index for core areas of regional financial centers in northeast China was released. The conference also held an unveiling ceremony for the upgrading of the Shenyang finance and trade development zone to a national-level development zone, and a launch ceremony of a platform for Shenyang industrial insights and decision analysis. The conference was co-hosted by China Economic Information Service, Liaoning Branch of Xinhua News Agency, Shenhe District People's Government, Shenyang local financial administration under guidance of Shenyang Municipal People's Government and Liaoning local financial supervision and administration bureau. Original link: https://en.imsilkroad.com/p/343777.html
GUANGZHOU, China, Nov. 26, 2024 /PRNewswire/ -- VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration will focus on gene vector and mRNA bioprocess solutions and services, accelerating the development and clinical translation of innovative biopharmaceutical projects. Building on years of successful collaboration, Sartorius and the VectorBuilder have agreed to further expand the scope of their partnership. The new cooperation will cover various areas, such as co-development of innovative downstream processes for cell and gene therapies; further optimization of the development platform and commercial production of GMP-compliant mRNA, plasmid and viral vectors; partnering to support the achievement of sustainability goals; and regular exchange as well as training of talent from both companies. Moreover, VectorBuilder will be a developing partner for applications in the field of the new modalities. "Sartorius is deeply committed to customer-centric innovation, which is the cornerstone of our product development and service provision," said Sarah Wang, Head of Sartorius China. "We anticipate that this strategic partnership will yield innovative solutions aimed at enhancing the efficiency and quality of biomedical enterprises. Together, we aim to support the growth of our global customers and the broader biomedical industry, and to contribute to the advancement of life sciences through transformative processes." "Innovation is in the DNA of VectorBuilder. This agreement with Sartorius allows us to further expand our reach and impact, empowering researchers and pharmaceutical companies worldwide with advanced gene delivery solutions," said Dr. Bruce Lahn, Founder and Chief Scientist of VectorBuilder. "We are excited to combine our expertise to create a more efficient and effective biopharmaceutical ecosystem." "By partnering with VectorBuilder, we look forward to leveraging the expertise of both companies to enable more innovations in downstream processing, further reducing time to market and ultimately saving more people's lives," Michaela Pischke added, Head of the Business Area Separation Technologies. "Congratulations to our China team who have done a great job in laying the groundwork to strengthen this partnership." Both companies are committed to exploring the vast potential of cell and gene therapies and accelerating the translation of research breakthroughs into life-saving treatments. About SartoriusSartorius | Biopharma, Laboratory, Applied & Life Sciences About VectorBuilderwww.vectorbuilder.com
By China Report ASEAN BEIJING, Sept. 24, 2024 /PRNewswire/ -- On September 19, a foreign journalists' tour themed "High-Quality Development at the New Border Gate," which was hosted by the Center for Asia-Pacific under the China International Communications Group, took place in the Daxing District of Beijing. A delegation of 19 journalists and vloggers from the United States, Japan, South Korea, Brazil, Myanmar, Indonesia, Vietnam, Thailand, and the Philippines visited a number of representative industrial parks of high-quality development in Daxing, including the Daxing Biomedical Industry Base, Daxing International Hydrogen Energy Demonstration Zone, and Daxing International Airport Economic Zone. This year marks the 10th anniversary of the implementation of the strategy for the coordinated development of the Beijing-Tianjin-Hebei region, and the 5th anniversary of Beijing Daxing International Airport. The Daxing District has seized the opportunities to explore an open economic development model with pioneering and innovative thinking. It has been committed to building not only a world-class modern international airport economic zone, but also a medical and health industry cluster, as well as a hydrogen energy industry demonstration zone. The delegation's first stop was the Zhongguancun Medical Device Park at the Daxing Biomedical Industry Base. Committed to building a world-class medical device innovation and entrepreneurship center, the park has attracted a great number of high-end medical device companies to set up offices. The journalists mainly visited the Huake Precision Medical Technology Co., Ltd. Foreign journalists visit the Huake Precision Medical Technology Co., Ltd. Huake Precision concentrates on the R&D, production, and technical services of high-end medical devices such as neurosurgical continuum robots. It is a Chinese leading enterprise of innovative neurosurgical medical equipment. Over the past six years of operation in Daxing Biomedical Industry Base, the company has witnessed improvements of the Industry Base in services, spatial environment, and business policies. According to Several Measures of Daxing District for Boosting the Medical and Health Industry, the district will pay a lump sum of 3 million yuan of financial support for each license of the three types of medical devices that have passed the national special examination procedure for innovative medical devices and the projects that have obtained the medical device registration certificates for commercial production within three years. Huake Precision boasts a number of products that have obtained this support. A person in charge said that the policy has been an important incentive for his company to attach importance to original innovation. During the visit, Myanmar journalist Si Thu Tun inserted a slender catheter into a model human skull to experience a neurosurgeon using the MR-guided laser ablation system to treat a patient with epilepsy. Other journalists were also quite interested in the procedure. They took over from Si Thu Tun and created short videos for their social media accounts. "I'm quite impressed with the eye-opening visit today, especially China's cutting-edge medical technology," said Indonesian journalist Antony Hardi. "Indonesians tend to travel to Singapore and Malaysia for better medical services. The two countries have thus developed 'medical tourism' projects. I think China's medical technology is on a par with them, and it's feasible for more Indonesians to come to China for healthcare treatment." In contrast to medical device enterprises such as Huake Precision, Zhima Health, a new sub-brand of Tongrentang—a top producer of traditional Chinese medicine (TCM) in China, has explored another development path for the medical and health industry. Established in 2019 in the context of the internet and the Internet of Things, Zhima Health is committed to enhancing the influence of TCM-based health concepts among the young people and exploring a healthy market for young consumers. TCM-based food and beverages were on sale at the Tongrentang Zhima Health No.0 Store located in the Daxing Biomedical Industry Base. The visiting journalists showed a strong interest in a coffee with barbary wolfberry and a Napoleon cake with spine date seeds and poria cocos. Philippine vlogger Char even bought a bottle of "good-night water"—a healthy drink with TCM formula. Under the guidance of the No. 0 Store staff, the journalists experienced making sachets with a variety of seasonal medicinal herbs. Noilublao Kongpob, a vlogger from Thailand, found it fun to make sachets. "This is a combination of the TCM culture with modern aesthetics," he observed, "Wearing sachets is similar to wearing perfume. If I have more time in the future, I would like to visit Daxing again to share even more with my friends in Thailand." After completing the visit to the Daxing Biomedical Industry Base, the delegation arrived in the Daxing International Hydrogen Energy Demonstration Zone, which opened in March 2022 and consists of a hydrogen exchange center, a hyper hydrogenation station, an incubator, and an office space. Driven by the "dual carbon" goals and the aspiration to build the district into one with industrial strength, Daxing has prioritized the development of hydrogen energy in its industrial layout. The journalists were quite interested in the hydrogen energy vehicle and hydrogen energy filling station on display. They asked a lot of questions about their R&D progress and prospects, as well as the cost of hydrogen energy vehicles in comparison with fossil fuel vehicles. Shortly before this tour, Si Thu Tun visited a hydrogen energy enterprise in Xinjiang's Hami Prefecture. Therefore, he was particularly excited about this event. "I saw a number of machines and vehicles driven by hydrogen today," he said, "and I was informed that other than water, hydrogen can be extracted from livestock waste. I'm delighted to see that China is vigorously developing the hydrogen technology and putting it into trial use at different locations." Nguyen Thi Thanh Thanh, a vlogger from Vietnam, said that the exhibition of the hydrogen energy industry had impressed her the most. "I knew about hydrogen as a new energy, but I was not aware that it could be applied in so many scenarios," she remarked. "Besides, Daxing had been known to me for its new airport, not for its advanced industries, such as medicine, energy, and robots. The visit today has been rewarding." At the end of the tour, the delegation visited the Daxing International Airport Economic Zone to get an overview of its development. Over the last five years since the opening of the Daxing International Airport, the economic zone has brought into full play the overlapping preferential policies for the zone to be built into "an airport economic zone, a free trade pilot zone, and an airport comprehensive bonded zone," aiming to build a high-level opening platform for the coordinated development of the Beijing-Tianjin-Hebei region. In the future, the economic zone will continue to promote the building of a world aviation city and upgrade the high-quality development in Daxing to a new level.
TAIPEI, Sept. 11, 2024 /PRNewswire/ -- The High-Value Biomaterials Research and Commercialization Center (HBRCC) at "National Taipei University of Technology" (NTUT) on July 26 held an international forum at the 2024 Bio Asia-Taiwan. The event gathered renowned biomaterial experts from across the globe, including Professor Takanori Ichiki from Tokyo University, Professor Yasuhiko Tabata from Kyoto University, Professor Yu-Chen Hu from "National Tsing Hua University", Professor Haytam Kasem from Azrieli College of Engineering Jerusalem, Professor Maziar Ramezani from Auckland University of Technology, and Deputy Director Lun-De Liao of the Institute of Biomedical Engineering and Nanomedicine (IBEN) at "National Health Research Institutes" (NHRI). Presided over by HBRCC Director Hsu-Wei Fang, the forum focused on models for international collaboration in biomaterials and sharing of experiences in industry-academia cooperation by the attending experts, with the aim of strengthening cross-border exchanges and jointly advancing research in the field of biomaterials. Leading professors from across the globe are pictured at the NTUT forum on the latest trends in biomaterial development and commercialization. (Photo courtesy of NTUT) NTUT and NHRI Ink MOU on Deepening Collaboration to Jointly Promote Taiwan's Biomedical IndustryAt the event, experts witnessed the signing of a memorandum of understanding (MOU) between NTUT and NHRI to promote academic and talent exchanges and to jointly advance technology transfer. Director Hsu-Wei Fang stated that the HBRCC has been working closely with NHRI in technology transfer projects, with successes including patents on an artificial tear solution in Japan and Taiwan, as well as assisting the NHRI in planning the commercialization of the research outcome. Director Fang expressed hopes that the MOU will spark new opportunities in Taiwan's biomaterials field. IBEN Director Lun-De Liao said that the NHRI is Taiwan's leading medical and biomedical research institute, and that the MOU with NTUT's HBRCC will bring closer collaboration in technical research, talent cultivation and technology transfer, bringing new momentum to joint efforts on propelling biomedical research and academia-industry collaborations. 3P Model to Further Enhance Technology Transfer and Development of Taiwan's Biomaterial IndustryDirector Hsu-Wei Fang stated that assisting professors in commercializing their findings into products has been a perennial question at his institution, which is in particularly challenging in biomedicine due to regulatory, safety, and efficacy considerations. He also noted that many countries and universities have different approaches to technology transfer. Deputy Director Lun-De Liao stated that the 3P (Public-Private Partnerships) model can potentially transform the mindset on academia-industry collaborations, bring greater benefits to both sides and advance Taiwan's biomaterials industry. Deputy Director Liao also expressed hopes to drive Taiwan's industry development with the 3P model. Taiwan, Japan, Israel, New Zealand to Strengthen Exchanges, Competitiveness Leveraging Taiwan's Industry AdvantagesProfessor Kasem suggested that international exchanges could start with joint authorship of papers between researchers of Israel and Taiwan, and later progress to joint efforts at securing patents to attract commercialization opportunities. On education, the two sides could establish joint courses to keep students abreast of global academic and industry trends as well as enhance their global vision and hands-on capabilities. Professor Maziar Ramezani recommended Taiwan to work with top global institutions and participate in global research networks, as well as ink bilateral agreements with countries excelling in biomedical research to deepen collaborations and elevate Taiwan's competitiveness. He also recommended Taiwan to leverage its advantages in the semiconductor and electronics sectors to gain an edge in the biomedical field. Professor Ichiki stated that Japan and Taiwan have been collaborating in the semiconductor sector, and that Taiwan's long-standing focus on nanotechnology will be key to advancing its biomedical industry and deepening collaboration with Japan. Professor Ichiki emphasized that students should familiarize themselves with domain knowledge to lower obstacles to academic-industry collaborations as well as broaden their resources and professional networks. In conclusion, Professor Yu-Chen Hu stated that most of the industry-academia collaborations in Taiwan are small-scale and mainly focused on addressing specific industry bottlenecks, and that such efforts should scale up to larger projects to better encourage joint development of innovative technologies or new drugs. However, he said that despite Taiwan's strengths in R&D, its biomanufacturing capabilities lags behind South Korea, China, and Singapore. To address this concern, strengthening biomanufacturing should be prioritized to ensure that Taiwan has the domestic capacity to develop and manufacture drugs. NTUT's HBRCC Hoping for New Global Horizons Through International CollaborationDirector Fang stated that founded during the Japanese occupation, NTUT is a century-old institution and that 10% of alumni currently hold leadership positions in Taiwan's publicly traded companies. He said that the university emphasizes both theory and practice as well as focuses on achieving technology transfer, adding that further improvements in resource integration, market insights are needed to accelerate development and build new Taiwanese brands. Noting that the HBRCC is well experienced in technology transfer, Director Fang said that he is looking forward to collating the attending experts' insights and forming closer international collaborations to jointly open new horizons in the global biomedical industries.
Powered by Core Strengths, Focus on Core Businesses & Reinforce Organic Growth Momentum 2024 Interim Results Highlights: Total revenue maintained growth, reaching RMB97.84 billion; Industrial operation profit maintained growth, reaching RMB3.47 billion; Continued focus on core businesses, with the four core subsidiaries generating total revenue of RMB72.17 billion, accounting for 74% of the Group's total revenue; Adjusted total debt-to-capital ratio was 50.2%, maintaining a downward trend since 2020; Global operation capabilities continued to improve, with overseas revenue reaching RMB45.87 billion, accounting for 47% of total revenue; Investment in technology innovation reached RMB3.5 billion, with the integrated innovation model becoming more mature and a number of groundbreaking innovations achieved; Asset-light operation capabilities have become more prominent; Collaboration with partners to develop major projects and establish industry funds, driving the future development of advantageous industries; the proportion of Club Med's self-owned resorts reduced to 15% HONG KONG and SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its interim results for the six months ended 30 June 2024 (the "Reporting Period"). In the first half of 2024, despite a complex macroeconomic environment, Fosun steadfastly pushed forward its strategic focus, driving development with core strengths, achieving quality and efficiency improvement in core industries, and maintaining a solid asset base. During the Reporting Period, the Group's revenue continued to grow, reaching RMB97.84 billion. Industrial operation profit maintained growth, reaching RMB3.47 billion, and profit attributable to owners of the parent was RMB720 million. The four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal, and Fosun Tourism Group ("FTG"), achieved a total revenue of RMB72.17 billion, maintaining year-on-year growth and accounting for 74% of the Group's total revenue. At the same time, Fosun continuously optimized its asset portfolio, continuously reduced leverage, maintained a sound financial position, and had abundant cash reserves, further strengthening its ability to seize opportunities and accumulate strength for a new round of development. As of the end of the Reporting Period, the Group's adjusted total debt-to-capital ratio was 50.2%, maintaining a downward trend since 2020. Adjusted NAV was HK$17.4 per share. In the 17 years since its listing, Fosun has accumulatively paid out HK$25.6 billion in dividends, with the dividend payout ratio gradually increasing to over 20% in the past five years. In June 2024, the international rating agency S&P fully recognized the effectiveness of Fosun's financial strategy and affirmed its rating outlook as "stable". Guo Guangchang, Chairman of Fosun International, said: "In the first half of the year, although the macro environment remained challenging, we continued to resolutely execute our strategy of focusing on core businesses, developing industry-leading companies and products in the industries where we have formed advantages. We have maintained our focus on innovation and globalization, while focusing on asset-light operations, driving long-term development with competitive core strengths." Steady growth in overseas revenue, with high-quality global business becoming a new growth driver As a global enterprise rooted in China, Fosun has leveraged its industrial presence in over 35 countries and regions around the world to connect different markets, formats, and resources, continuously enhancing its global operation capabilities. In the first half of 2024, the Group's overseas revenue reached RMB45.87 billion, representing a year-on-year increase of 4%, and accounting for 47% of total revenue. High-quality global business has gradually become a new growth driver. HANQUYOU, independently developed by Shanghai Henlius, received marketing approval from the United States (U.S.) Food and Drug Administration (FDA), making it a "Chinese" monoclonal antibody biosimilar approved in China, the European Union (EU), and the U.S. HANLIKANG, China's first biosimilar, received marketing approval from the Peruvian General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru, making it the third self-developed drug of Shanghai Henlius to be approved for overseas marketing after HANQUYOU and HANSIZHUANG. Club Med, a subsidiary of FTG, operates 67 resorts worldwide. In the first half of 2024, it achieved a record-high business volume of RMB8.89 billion, representing a year-on-year increase of 10.3%. Club Med's business in the Europe, Middle East and Africa (EMEA) region and the Americas continued to grow, and its business in Asia-Pacific region recovered significantly. In May 2024, Club Med signed an agreement with Oman for the launch of its first resort in the Middle East. Easun Technology, a global leading automation and digitalization company under Fosun, achieved new overseas orders of RMB3.99 billion in the first half of 2024, with a significant increase in orders from the U.S. market, reaching RMB750 million, more than doubling year-on-year. Hainan Mining's Bougouni lithium mine project in Mali, Africa, is undergoing the first phase of construction and is expected to be completed and put into operation by the end of 2024. In July 2024, Hainan Mining reached a memorandum of understanding with Ajlan & Bros Mining Company to explore the feasibility of jointly building a lithium salt plant in Saudi Arabia and jointly establish an industry fund. Fosun Insurance Portugal continued its high-quality development in the first half of 2024, achieving both domestic and international business growth. The contribution from overseas markets further increased, with international business recording premiums of EUR885 million, accounting for over 30% of the total premiums; the net profit of international business was approximately EUR51 million, accounting for over 40%. Integrated innovation model has become more mature, with a number of achievements transforming into growth drivers Innovation is a core competence that Fosun has accumulated over a long period of time and has always adhered to. During the Reporting Period, the Group invested a total of RMB3.5 billion to deepen its technological and innovation capabilities. Since 2024, Fosun's integrated innovation model under a global vision has become more mature, and a number of groundbreaking achievements are continuously being transformed into growth drivers. In terms of innovative drug R&D, Fosun Pharma has 4 products with a total of 9 indications were approved for marketing; 4 products with a total of 9 indications had entered the pre-launch approval stage/ key clinical stage; and 9 products (by indication) have been approved to conduct clinical trials. Shanghai Henlius' independently developed and manufactured innovative biologics continue to make breakthroughs. The world's first anti-PD-1 monoclonal antibody for the first-line treatment of small cell lung cancer (SCLC), HANSIZHUANG, has been approved for 4 indications, benefiting over 75,000 patients. It has also been out-licensed to over 70 countries and regions, including the U.S., Europe, Southeast Asia, the Middle East, and North Africa. In addition, the new indication for SUKEXIN, a new generation of oral thrombopoietin receptor agonist (TPO-RA), has been approved by the National Medical Products Administration (NMPA). New progress has also been made in the deployment of cutting-edge medical devices and innovative therapies. In June 2024, Intuitive Fosun Headquarters Industrial Base was inaugurated in Shanghai, is the largest integrated R&D, production and training base of Intuitive Surgical in the Asia-Pacific region, significantly accelerating the localization of the da Vinci surgical robot. Intuitive Fosun's Ion robotic bronchoscopy was launched in July. Leveraging its successful experience in international cooperation, Fosun Pharma and Insightec established a joint venture, Fosun-Insightec, in February 2024. The joint venture is focused on the commercialization, clinical application and research of resonance image guided focused ultrasound brain therapy system (i.e. MRgFUS brain therapy system, Exablate Neuro) in the Chinese mainland, Hong Kong SAR, and Macau SAR. Fosun's innovative genes are deeply integrated into its member companies. In addition to R&D innovation, it has also achieved remarkable achievements in product innovation, marketing innovation, and digitalization. Club Med launched a new booking system & engine, with independent bookings increasing by 16% compared to 2019. Fosun Insurance Portugal's MyFidelidade App has over 1.6 million registered users, exceeding 15% of Portugal's total population, with digital channel sales increasing by 16% year-on-year. Sunvisioncapital Tourism has further upgraded its product portfolio. The "Silk Road Express", built according to international tourist train standard, was launched. Yuyuan's Nanxiang Steamed Bun Restaurant has teamed up with Balenciaga, Tong Han Chun Tang and THE BEAST jointly created new products and made a big hit. Focus on asset-light operations and capture new development opportunities Leveraging its profound industrial operation capabilities built up over 30 years of investment in heavy assets, Fosun has keenly captured asset-light development opportunities in the new market environment and has continuously made breakthroughs. In the cultural tourism sector, Fosun's asset-light operation model has achieved remarkable results, with IPs such as Club Med, Atlantis Sanya, and Taicang Alps becoming benchmarks in the domestic tourism industry. During the Reporting Period, 85% of Club Med resorts adopted a leasing and management model, with the proportion of self-owned resorts declining to 15%. In June 2024, FTG joined hands with the Taicang Municipal Government to build the phase II of Taicang Alps Resort, a one-stop ice and snow-themed urban tourist destination. The phase II project, with a total investment of over RMB5 billion, is funded by the Taicang Municipal Government and operated and managed by FTG. In May 2024, Fosun sold all of its 99.74% stake in German private bank HAL. After the completion of the transaction, Fosun will no longer hold any shares in HAL, but will retain the HAFS asset servicing business, managing approximately EUR100 billion in assets in an asset-light operation model. At the same time, Fosun has joined hands with partners to set up a number of industry funds to drive the future of advantageous industries. In March 2024, Fosun Pharma joined hands with Shenzhen Guidance Fund and seven other investors to jointly establish a RMB5.0 billion biomedical industry fund. Shanghai Fujian Equity Investment Fund Management, a subsidiary of Fosun Pharma, is exclusively managed this fund. In April, the Shenzhen Municipal Government and Fosun signed a strategic cooperation framework agreement, both parties will further strengthen cooperation in areas such as biomedicine, cultural and sports tourism, and fashionable consumption. In April 2024, Fosun Capital, together with Wuhan Innovation Investment and Wuhan Fund, established a RMB3.0 billion industry fund with an initial scale of RMB1.1 billion. This is the first batch of market-oriented fund invested by Hubei Province since the establishment of the RMB20.0 billion government guidance fund, mainly focusing on the four major sectors of new generation information technology, dual carbon, intelligent manufacturing, and consumption. In the future, Fosun will continue to focus on asset-light operations, continuously expand its "circle of friends", strengthen in-depth cooperation with all parties, and achieve win-win results through complementing each other's advantages. Industry-leading ESG performance and ongoing philanthropic Initiatives Since its establishment 32 years ago, Fosun has steadfastly upheld its corporate values of "Self-improvement, Teamwork, Performance, and Contribution to Society". Fosun has achieved excellent ESG (Environmental, Social, and Governance) performance. As of the end of the Reporting Period, Fosun's MSCI ESG rating remained at AA, making it the only conglomerate in Greater China with an AA rating. In addition, during the Reporting Period, Fosun was selected as the top 1% in S&P Global's "Sustainability Yearbook 2024 (China Edition)" and was recognized as an "Industry Mover", outperforming 90% of companies worldwide. In terms of social welfare, Fosun has continuously contributed to the "China solution" to aid Africa. Fosun Pharma announced that it will donate artemisinin-based antimalarial drugs worth RMB10 million to Africa in the next three years to support the health development of African communities. The Rural Doctor Program, which has been running for seven years, has now covered 78 counties in 16 provinces, municipalities, and autonomous regions across the country, supporting 25,000 rural doctors and benefiting 3 million grassroots families. In the first half of 2024, the program insured rural doctors with over 7,000 group accident insurance and critical illness insurance policies, upgraded 38 health offices (centres) in 9 counties to intelligent ones, and trained over 1,000 rural doctors online. Looking ahead, Guo Guangchang said: "Fosun will continue to focus on its core businesses, enhance its operational capabilities in advantageous industries, actively invest and expand in advantageous sectors, make forward-looking plans, and seize more development opportunities with its asset-light operation capabilities. We will adhere to innovation, steadfastly advance our globalization strategy, and build a sustainable and stable profitable enterprise, endeavoring to bring more world-class products and services to families worldwide." About Fosun Fosun was founded in 1992. After more than 30 years of development, Fosun has become a global innovation-driven consumer group. Adhering to the mission of creating happier lives for families worldwide, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of one billion families in health, happiness and wealth. In 2007, Fosun International Limited was listed on the main board of the Hong Kong Stock Exchange (HKEX stock code: 00656). As of 30 June 2024, Fosun International's total assets amounted to RMB821.9 billion; it received an AA MSCI ESG rating and was the only conglomerate in Greater China with such rating.
A12 藝術空間
Biomedical Industry
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
